Literature DB >> 16845448

Refractory septic shock: efficacy and safety of very high doses of norepinephrine.

S Katsaragakis1, A Kapralou, D Theodorou, H Markogiannakis, A Larentzakis, K M Stamou, P Drimousis, I Bramis.   

Abstract

The aim of this study was to evaluate the safety, efficacy, and effects of administration of very high doses of norepinephrine (> 4 microg kg(-1) min(-1)) in catecholamine-resistant septic shock. We reviewed the charts of all patients with nonresponding to commonly used norepinephrine doses (< or = 4 microg kg(-1) min(-1)) septic shock from January 1999 to December 2002 in our Surgical Intensive Care Unit. All patients were treated with high norepinephrine doses (> 4 microg kg(-1) min(-1)), after initial resuscitation, so as to achieve a mean arterial pressure higher than or equal to 65 mmHg. During this 4-year period, 12 consecutive patients with catecholamine-resistant septic shock were included in our study. When compared with the values obtained prior to the administration of very high norepinephrine doses, the values of mean arterial pressure (p = 0.003) and systemic vascular resistance (p = 0.002) significantly increased after the administration of such doses, and additionally, lactate concentrations (p = 0.003) decreased. In contrast, no significant changes were observed regarding mean central venous pressure, pulmonary capillary wedge pressure, and pulmonary arterial pressure. Administration of high norepinephrine doses in our patients resulted in a survival rate of 33.4%. Management of catecholamine-resistant septic shock patients poses a challenging problem. Administration of very high norepinephrine doses is safe and effective and may improve survival of these patients with otherwise extremely high mortality rates. Copyright 2006 Prous Science.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16845448     DOI: 10.1358/mf.2006.28.5.990203

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  6 in total

1.  Survival after shock requiring high-dose vasopressor therapy.

Authors:  Samuel M Brown; Michael J Lanspa; Jason P Jones; Kathryn G Kuttler; Yao Li; Rick Carlson; Russell R Miller; Eliotte L Hirshberg; Colin K Grissom; Alan H Morris
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

Review 2.  Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside.

Authors:  B Levy; S Collin; N Sennoun; N Ducrocq; A Kimmoun; P Asfar; P Perez; F Meziani
Journal:  Intensive Care Med       Date:  2010-09-23       Impact factor: 17.440

3.  Catecholamine dosing and survival in adult intensive care unit patients.

Authors:  Marc Kastrup; Jan Braun; Magnus Kaffarnik; Vera von Dossow-Hanfstingl; Robert Ahlborn; Klaus-D Wernecke; Claudia Spies
Journal:  World J Surg       Date:  2013-04       Impact factor: 3.352

4.  Outcome of patients with septic shock and high-dose vasopressor therapy.

Authors:  Thomas Auchet; Marie-Alix Regnier; Nicolas Girerd; Bruno Levy
Journal:  Ann Intensive Care       Date:  2017-04-20       Impact factor: 6.925

5.  Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial.

Authors:  Martin W Dünser; Esko Ruokonen; Ville Pettilä; Hanno Ulmer; Christian Torgersen; Christian A Schmittinger; Stephan Jakob; Jukka Takala
Journal:  Crit Care       Date:  2009-11-16       Impact factor: 9.097

6.  Angiotensin II: a new approach for refractory shock management?

Authors:  Antoine Kimmoun; Bruno Levy
Journal:  Crit Care       Date:  2014-12-18       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.